Back to Search
NICHOLAS SHIH, D.O.
D.O.
Student in an Organized Health Care Education/Training Program
NPI: 1316351083IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
CMS Specialties
PrimaryFAMILY PRACTICE
Education
MICHIGAN STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Class of 2014
Research & Publications (20)
Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.
PMID 19655245·Breast Cancer Res Treat·2010
8-other
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
PMID 19196021·J Med Chem·2009
7-preclinical
Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine.
PMID 19342969·J Immunother·2009
7-preclinical
Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway.
PMID 19166932·Cell Signal·2009
7-preclinical
Potent aza-peptide derived inhibitors of HCV NS3 protease.
PMID 19596195·Bioorg Med Chem Lett·2009
8-other
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
PMID 19102654·J Med Chem·2009
8-other
Mechanical stretch induces endothelial nitric oxide synthase gene expression in neonatal rat cardiomyocytes.
PMID 19673940·Clin Exp Pharmacol Physiol·2009
7-preclinical
Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
PMID 19054672·Bioorg Med Chem Lett·2009
8-other
Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands.
PMID 18752952·Bioorg Med Chem Lett·2008
7-preclinical
Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
PMID 18193821·Acc Chem Res·2008
6-review
Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
PMID 18547807·Bioorg Med Chem Lett·2008
8-other
Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.
PMID 17683932·Bioorg Med Chem Lett·2007
7-preclinical
Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells.
PMID 17705854·BMC Mol Biol·2007
7-preclinical
Chicken single-chain variable fragments against the SARS-CoV spike protein.
PMID 17643500·J Virol Methods·2007
7-preclinical
Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
PMID 17608487·Org Lett·2007
8-other
The polymorphisms of Eotaxin 1 and CCR3 genes influence on serum IgE, Eotaxin levels and mild asthmatic children in Taiwan.
PMID 17845580·Allergy·2007
8-other
Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.
PMID 17466519·Bioorg Med Chem Lett·2007
7-preclinical
Association of interferon-gamma and interferon regulatory factor 1 polymorphisms with asthma in a family-based association study in Taiwan.
PMID 16961714·Clin Exp Allergy·2006
8-other
Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes.
PMID 17020980·Clin Cancer Res·2006
4-observational
Effect of seropositive rheumatoid factor on cardiac troponin I measurement using the Access immunoassay analyzer.
PMID 17032145·Clin Chem Lab Med·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7007 POWERS BLVD
PARMA, OH 44129 - Phone
- (216) 303-5941
Quick Facts
- NPI
- 1316351083
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile